|
Laxman Pai, Opalesque Asia: Chicago-based ARCH Venture Partners announced two new venture capital funds to invest in early-stage biotech companies with a combined total of $1.46 billion. They are ARCH Venture Fund X and ARCH Venture Fund X Overage.
ARCH formed in 1986 and made early investments in biotechs such as cancer cellular-therapy company Juno Therapeutics Inc., which went public in 2015 and was acquired by Celgene Corp. in 2018 for $9 billion.
Limited partners include endowments, family offices, sovereign wealth funds, and other institutional investors, said a press note from the life sciences investor.
Led by Robert Nelsen, Keith Crandell, Kristina Burow, Mark McDonnell, Steve Gillis, and Paul Thurk, Arch Venture Partners invests in advanced technology companies commercializing technologies developed at academic institutions, corporate research groups, and national laboratories. The firm invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.
"ARCH has always been driven to invest in great science to impact human health. There isn't a better illustration of our principles than our all-in battle against COVID-19. The healthcare revolution will be accelerated by the changes that are happening now and we are excited to continue to invest aggressively in risk-takers doing truly transformational science," said co-founder and Managing Director Robert Nel...................... To view our full article Click here
|
RSS
